荷癌小鼠中的免疫黏附和补体
Immunoadherence and complement in cancer-bearing mice.
作者信息
Porta C, Villa M L, Clerici E
出版信息
Br J Cancer. 1978 Jan;37(1):23-7. doi: 10.1038/bjc.1978.3.
Abstract
Shortly after grafting of Ehrlich ascites carcinoma cells, the serum of tumour-bearing mice loses the capacity to mediate immunoadherence phenomena, because of a sharp decrease in the concentration of C3b and C3d, while the cellular receptors for such factors are unaffected by tumour growth. It is suggested that complement is consumed through the alternative pathway which is activated during the inflammatory responses accompanying tumour growth.
摘要
艾氏腹水癌细胞移植后不久，荷瘤小鼠血清介导免疫黏附现象的能力丧失，原因是C3b和C3d浓度急剧下降，而这些因子的细胞受体不受肿瘤生长影响。提示补体通过替代途径被消耗，该途径在肿瘤生长伴随的炎症反应中被激活。
相似文献
1
Immunoadherence and complement in cancer-bearing mice.荷癌小鼠中的免疫黏附和补体
Br J Cancer. 1978 Jan;37(1):23-7. doi: 10.1038/bjc.1978.3.
2
3
[Enhancement of the therapeutic effect and red cell immune function by radix Trichosanthis in mice bearing Ehrlich ascites carcinoma].[天花粉对艾氏腹水癌荷瘤小鼠治疗作用及红细胞免疫功能的增强作用]
Zhong Xi Yi Jie He Za Zhi. 1989 Jul;9(7):418-20, 390.
4
Interaction of target cell-bound C3bi and C3d with human lymphocyte receptors. Enhancement of antibody-mediated cellular cytotoxicity.靶细胞结合的C3bi和C3d与人淋巴细胞受体的相互作用。抗体介导的细胞毒性增强。
J Exp Med. 1981 Jun 1;153(6):1592-603. doi: 10.1084/jem.153.6.1592.
5
6
7
8
Complement receptors (C3b, C4b/C3d) unbalance on CLL lymphocytes.慢性淋巴细胞白血病（CLL）淋巴细胞上补体受体（C3b、C4b/C3d）失衡。
Boll Ist Sieroter Milan. 1976 Jul 31;55(3):235-40.
9
Ehrlich ascites cells activate the alternative pathway of the human complement system.艾氏腹水细胞激活人类补体系统的替代途径。
Immunobiology. 1984 May;166(4-5):397-402. doi: 10.1016/S0171-2985(84)80017-0.
10
Action of the C3b-inactivator on the cell-bound C3b.C3b灭活剂对细胞结合C3b的作用。
J Immunol. 1979 Mar;122(3):759-65.
本文引用的文献
1
THE COMPLEMENT CONTENT OF THE SERUM OF NORMAL AS OPPOSED TO TUMOUR BEARING MICE.正常小鼠与患肿瘤小鼠血清中的补体含量
Br J Cancer. 1964 Dec;18(4):714-20. doi: 10.1038/bjc.1964.82.
2
SERUM COMPLEMENT LEVELS IN HUMAN CANCER.人类癌症中的血清补体水平
J Philipp Med Assoc. 1964 Nov;40:839-46.
3
[STUDY OF VARIATIONS IN THE COMPLEMENT LEVEL IN THE COURSE OF CANCER CHEMOTHERAPY].[癌症化疗过程中补体水平变化的研究]
Acta Unio Int Contra Cancrum. 1964;20:411-5.
4
Serum complement and bacteriophage neutralization titers in human infections, leukemias, and lymphomas.人类感染、白血病和淋巴瘤中的血清补体及噬菌体中和滴度。
J Lab Clin Med. 1960 Oct;56:594-606.
5
Serum levels of second component of complement in cancer patients.癌症患者血清补体第二成分水平。
J Immunol. 1966 Sep;97(3):331-7.
6
Serum complement level in patients with leukemia.白血病患者的血清补体水平。
Int J Cancer. 1969 Nov 15;4(6):845-51. doi: 10.1002/ijc.2910040613.
7
Tissue localization of two populations of human lymphocytes distinguished by membrane receptors.通过膜受体区分的两类人淋巴细胞的组织定位
J Immunol. 1972 May;108(5):1456-60.
8
Serum-mediated leukemia cell destruction in AKR mice.血清介导的AKR小鼠白血病细胞破坏
J Exp Med. 1973 Oct 1;138(4):925-38. doi: 10.1084/jem.138.4.925.
9
Evidence for in vivo reaction of antibody and complement to surface antigens of human cancer cells.抗体和补体对人癌细胞表面抗原的体内反应证据。
Science. 1974 Nov 1;186(4162):454-6. doi: 10.1126/science.186.4162.454.
10
In vitro synthesis of factor B of the alternative pathway of complement activation by mouse peritoneal macrophages.小鼠腹腔巨噬细胞对补体激活替代途径中B因子的体外合成
Eur J Immunol. 1976 Jun;6(6):393-8. doi: 10.1002/eji.1830060604.
Zotero 插件